Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 12, 2010, Pages

  Salazar, Carlos A ^a   Malaga, German ^a   Malasquez, Giuliana ^a  

^a UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; DABIGATRAN; DESULFATOHIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN; XIMELAGATRAN; ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; AZETIDINE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; BENZYLAMINE DERIVATIVE; DABIGATRAN ETEXILATE; PYRIDINE DERIVATIVE; THROMBIN; VITAMIN K GROUP;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALL CAUSE MORTALITY; ANTICOAGULANT THERAPY; BLEEDING; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INCIDENCE; LIVER DISEASE; LUNG EMBOLISM; MORBIDITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SKIN NECROSIS; SYSTEMATIC REVIEW; THROMBOSIS PREVENTION; TOTAL KNEE ARTHROPLASTY; VENOUS THROMBOEMBOLISM; DRUG ANTAGONISM; DRUG CONTRAINDICATION; HIP ARTHROPLASTY; KNEE ARTHROPLASTY; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL;

ANTICOAGULANTS; ANTIFIBRINOLYTIC AGENTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; AZETIDINES; BENZIMIDAZOLES; BENZYLAMINES; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBIN; VENOUS THROMBOEMBOLISM; VITAMIN K; WARFARIN;

EID: 77952466576     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD005981.pub2     Document Type: Review

References (115)

1. Eriksson BI, Dahl OE, Buller HR, Hettiarachchi R, Rosencher N, Bravo ML, et al. BISTRO II Study Group. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. Journal of Thrombosis and Haemostasis 2005;3(1):103-11.
2. Colwell CW Jr, Berkowitz SD, Davidson BL, Lotke PA, Ginsberg JS, Lieberman JR, et al. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. Journal of Thrombosis and Haemostasis 2003;1(10):2119-30.
3. Colwell CW, Berkowitz SD, Davidson BL, Lotke PA, Ginsberg JS, Lieberman JR, et al. Randomized, double-blind, comparison of Ximelagatran, an oral direct thrombin iInhibitor, and Enoxaparin to prevent venous thromboembolism (VTE) after total hip arthroplasty (THA). Blood 2001;98(11):Abstract 2952.
4. Eriksson BI, Baur M, Ekman S, Lindbratt S, Bach D, Kalebo P, et al. Recombinant hirudin, desirudin (TMREVASC), is more effective than enoxaparin as prophylaxis of thromboembolic complications in patients undergoing total hip replacement. Thrombosis and Haemostasis 1997;564(Supplement June):Abstract No PD-2309.
5. Eriksson BI, Baur M, Lindbratt S, Bach D, Ekman S, Close P. Recombinant hirudin, CGP 39393, (TMREVASC), is more effective than enoxaparin as prophylaxis of thromboembolic complications in patients undergoing total hip replacement [Abstract]. Journal of Bone and Joint Surgery British 1997;79-B(Suppl.1):95-6.
6. Eriksson BI, Wille-Jorgensen P, Kalebo P, Mouret P, Rosencher N, Bosch P, et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. New England Journal of Medicine 1997;337(19):1329-35.
7. Eriksson BI, Wille-Jorgensen P, Kalebo P, et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. Journal of Vascular and Interventional Radiology 1998;9(3):530.
8. Hauer W, Sinz G, Hiesser H. Hirudin versus enoxaparin as prophylaxis of venous thromboembolism in patients undergoing total hip replacement. Annals of Hematology 1997;74(Suppl 2):A 130.
9. Mouret P, Eriksson B, Wille-Jorgensen P, Kalebo P, Rosencher N, Bosch P, et al. A comparison of recombination hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. Annals of Hematology 1998;76(Suppl I):A 11.
10. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Lassen MR, Mouret P, et al. The oral direct thrombin inhibitor ximelagatran, and its subcutaneous form melagatran, compared with enoxaparin for prophylaxis of venous thromboembolism (VTE) in total hip or total knee replacement: the EXPRESS study. Blood 2002;100(11 pt2):abstract 299.
11. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Lassen MR, Mouret P, et al. EXPRESS Study Group. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. Journal of Thrombosis and Haemostasis 2003;1(12):2490-6.
12. Glynn O. The express study: preliminary results. International Journal of Clinical Practice 2003;57(1):57-9.
13. Peters F, Cohen AT, Agnelli G, Dahl OE, Eriksson BI, Kalebo P. Ximelagatran and its subcutaneous form melagatran, versus enoxaparin as thromboprophylaxis in total hip or total knee replacement. British Journal of Haematology 2003;121(Suppl 1):42.
14. Colwell CW. EXULT B: More ximelagatran results in VTE prophylaxis after total knee replacement. Abstract of the Annual Meeting of the American Society of Hematology (http://www.theheart.org/article/231713.do). (accessed 10 May 2006).
15. Colwell CW Jr, Berkowitz SD, Lieberman JR, Comp PC, Ginsberg JS, Paiement G, et al. Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. Journal of Bone and Joint Surgery - American Volume 2005;87(10):2169-77.
16. Colwell CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, et al. Randomized, double-blind comparison of ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee replacement (TKR): EXULT B. Blood 2003;102(11):Abstract 39.
17. Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, et al. Randomized, double-blind comparison of ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee replacement (TKR). Journal of Thrombosis and Haemostasis 2003;1(Suppl 1):Abstract P1912.
18. Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, et al. EXULT A Study Group. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. New England Journal of Medicine 2003;349(18):1703-12.
19. Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement GD, et al. Randomized, double-blind, comparison of ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee replacement (TKR). Blood 2002;100(11 pt 2):Abstract 300.
20. Francis CW, Davidson BL, Berkowitz SD, Lotke PA, Ginsberg JS, Lieberman JR, et al. Randomized double-blind, comparative study of ximelagatran (pINN, formerly H 376/95), an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee arthroplasty (TKA). Thrombosis and Haemostasis 2001;July Suppl:Abstract OC44.
21. Francis CW, Davidson BL, Berkowitz SD, Lotke PA, Ginsberg JS, Lieberman JR, et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Annals of Internal Medicine 2002;137(8):648-55.
22. Heit JA, Colwell CW, Francis CW, Ginsberg JS, Berkowitz SD, Whipple J, et al. Astrazeneca Arthroplasty Study Group. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: A phase 2 dose-finding study. Archives of Internal Medicine 2001;161(18):2215-21.
23. Eriksson BI, Arfwidsson AC, Frison L, Eriksson UG, Bylock A, Kalebo P, et al. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery. Thrombosis & Haemostasis 2002;87(2):231-37.
24. Eriksson BI, Bergqvist D, Kalebo P, Dahl OE, Lindbratt S, Bylock A, et al. Melagatran for Thrombin, inhibition in Orthopaedic Surgery. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002;360(9344):1441-47.
25. Eriksson BI, Lindbratt S, Kalebo P. Methro II: dose-response study of the novel oral, direct thrombin inhibotor, H 376/95 and its subcutaneous formulation melagatran, compared with dalteparin as thromboembolic prophylaxis after total hip knee replacement. Haemostasis 2000;30(Suppl 1):20-1.
26. Dahl O, Eriksson B, Agnelli G, Cohen A, Mouret P, Rosencher N, et al. ASA and NSAIDs with Melagatran/Ximelagatran or Enoxaparin Do NOT Increase Bleeding in Patients Undergoing Joint Replacement Surgery. The METHRO III Study. Journal of Thrombosis and Haemostasis 2005;3(1):Abstract P 1627.
27. Dahl OE, Eriksson BI, Agnelli G, Cohen AT, Mouret P, Rosencher N, et al. Postoperative melagatran/ximelagatran for the prevention of venous thromboembolism following major elective orthopaedic surgery: Effects of timing of first dose and risk factors for thromboembolism and bleeding complications on efficacy and safety. Clinical Drug Investigation 2005;25(1): 2005;25(1):65-77.
28. Eriksson BI, Agnelli G, Cohen A, Dahl O, Mouret P, Rosencher N, et al. Significantly lower need for blood transfusions associated with post-operatively initiated subcutaneous melagatran/oral ximelagatran compared with enoxaparin. Thrombosis and Haemostasis 2004;92(2):428-30.
29. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Mouret P, Rosencher N, et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thrombosis and Haemostasis 2003;89(2):288-96.
30. Ginsberg JS, Davidson BL, Comp PC, Francis CW, MD, Friedman RJ, Huo MH, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. The Journal of Arthroplasty 2009;24(1):1-9.
31. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk, CN, Frostick SP, etal. RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. Journal of Thrombosis and Haemostasis 2007;5(11):2178-85.
32. Eriksson BI, Dahl OE, van Dijk CN, Frostick SP, Kurth AA, Rosencher N, et al. A new oral aniticoagulant, dabigatran etexilate, is effective and safe in preventing venous thromboembolism after total knee replacement surgery (The RE-MODEL Trial). Blood 2006;108:173.
33. Eriksson, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. (Erratum). Lancet 2007;370:2003.
34. Kurth AA, Dahl OE, van-Dijk CN, Eriksson BI, Frostick SP, Rosencher N, et al. A new oral anticoagulant, dabigatran etexilate, is effective and safe for the prevention of venous thromboembolism after total knee replacement. The Journal of Bone and Joint Surgery 2009;91-B(SUPP_I):7b.
35. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, doubleblind, non-inferiority trial. Lancet 2007;370(9591):949-56.
36. Cofrancesco E, Cortellaro M, Leonardi P, Corradi A, Ravasi F, Bertocchi F. Markers of hemostatic system activation during thromboprophylaxis with recombinant hirudin in total hip replacement. Thrombosis and Haemostasis 1996;75(3):407-11.
37. Ekman S, Eriksson BI, Lindbratt S, Toerholm C, Kalebo P, Baur M, et al. Recombinant hirudin, CGP 39393 15 mg (TMRevasc-Ciba), is the most effective and safe prophylaxis of thromboembolic complications in patients undergoing total hip replacement. Thrombosis and Haemostasis 1995;73(6):1093-Abstract No 737.
38. Eriksson BI, Ekman S, Kälebo P, Zachrisson B, Bach D, Close P. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet 1996;347(9002):635-9.
39. Eriksson BI, Ogren M, Eriksson UG, Kalebo P, Ahnfelt L, Bjorkstrom S, et al. Prophylaxis of venous thromboembolism with subcutaneous melagatran in total hip or total knee replacement: Results from Phase II studies. Thrombosis Research 2002;105(5):371-8.
40. Eriksson BI. Clinical experience of melagatran/ximelagatran in major orthopaedic surgery. Thrombosis Research 2003;109(Suppl 1):S23-S29.
41. Eriksson UG, Mandema JW, Karlsson MO, Frison L, Gisleskog PO, Wählby U, et al. Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis. Clinical Pharmacokinetics 2003;42(2):687-701.
42. Agnelli G, Eriksson BI, Cohen AT, Bergqvist D, Dahl OE, Lassen MR, et al. Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran. Thrombosis Research 2009;123(3):488-97.
43. Anon. Melagatran/ximelagatran versus enoxaparin for the prevention of venous thromboembolic events (EXTEND 2006). ClinicalTrials gov [www clinicaltrials gov] 2006 December 7 [cited 2007 Oct].
44. Harenberg J, Jöerg I, Weiss C. Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran. European Journal of Clinical Pharmacology 2006;62(3):173-7.
45. Mouret P. The oral direct thrombin inhibitor ximelagatran prophylaxis of venous thromboembolism in hip and knee replacement. Hamostaseologie 2002;22(3):103-6.
46. Eriksson BI, Borris L, Dahl OE, Haas S, Huisman MV, Kakkar AK, et al. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. Journal of Thrombosis and Haemostasis 2006;4(1):121-8.
47. Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, et al. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement [see comment]. Circulation 2006;114(22):2374-81.
48. Eriksson BI, Borris LC, Dahl OE, Haas SK, Huisman MV, Kakkar AK, et al. Prevention of venous thromboembolism with an oral, direct factor Xa inhibitor - BAY 59-7939 - in elective hip replacement: A dose-ranging study. Thrombosis and Haemostasis 2005;3:Abstract number: OR062.
49. Turpie AG, Fisher WD, Bauer K, Kwong L, Gent M, Misselwitz F. An oral, direct factor Xa inhibitor - BAY 59-7939 - for prophylaxis against venous thromboembolism after total knee replacement: A dose-ranging study. Journal of Thrombosis and Haemostasis 2005;3(1):Abstract number: OR063.
50. Turpie AG, Fisher WD, Bauer KA, Kwong LM, Irwin MW, Kalebo P, et al. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. Journal of Thrombosis and Haemostasis 2005;3(11):2479-86.
51. Eriksson BI, Turpie AG, Lassen MR, Prins MH, Agnelli G, Kalebo P, et al. A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery. Thrombosis and Haemostasis 2007;5(8):1660-5.
52. Eriksson BI, Turpie AGG, Lassen MR, Prins MH, Agnelli G, Gaillard ML, et al. YM150, an oral direct factor Xa inhibitor, as prophylaxis for venous thromboembolism in patients with elective primary hip replacement surgery. A dose escalation study. Blood 2005;106(11):Abstract 1865.
53. Lassen MR, Turpie AG, Rosencher N, Borris LC, Ageno W, Lieberman JR, et al. Rivaroxaban: An oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in total knee replacement surgery - Results of the RECORD 3 study. XXIst Congress of the International Society on Thrombosis and Haemostasis. 2007:Abstract.
54. Trocniz IF, Tillmann C, Liesenfeld KH, Schfer HG, Stangier J. Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery. Journal of Clinical Pharmacology 2007;47:371-82.
55. Turpie AG, Fisher WD, Bauer KA, Kwong LM, Irwin MW, Kälebo P, et al. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. Journal of Thrombosis and Haemostasis 2005;11:2479-86.
56. Wahlander K, Larson G, Lindahl TL, Andersson C, Frison L, Gustafsson D, et al. Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery. Thrombosis and Haemostasis 2002;87(4):580-5.
57. Dabigatran Etexilate Compared With Enoxaparin in Prevention of VTE Following Total Hip Arthroplasty. Ongoing study March 2008. Estimated Enrollment:1920 patients.
58. Albers GW, Diener HC, Frison L, Grind M, Nevinson M, Partridge S, et al. SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005;293(6):690-8.
59. Ansari S, Warwick D, Ackroyd CE, Newman JH. Incidence of fatal pulmonary embolism after 1, 390 knee arthroplasties without routine prophylactic anticoagulation, except in high-risk cases. Journal of Arthroplasty 1997;12(6):599-602.
60. Ansell J, Hirsh J, Dalen J, Bussey H, Anderson D, Poller L, et al. Managing oral anticoagulant therapy. Chest 2001;119(Suppl 1):22S-38S.
61. Clagett GP, Anderson FA Jr, Geerts W, Heit JA, Knudson M, Lieberman JR, et al. Prevention of venous thromboembolism. Chest 1998;114(5 Supplement):531S-60S.
62. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
63. Desai M. Division of Cardiovascular and Renal Drug Products. NDA 21-686, Ximelagatran (H376/95). Indication: Prevention of stroke and thromboembolic complications associated with atrial fibrillation. www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4069B1_06_FDA-Backgrounder-C-R-MOR.pdf (accessed May 2005).
64. Douketis JD, Eikelboom JW, Quinlan DJ, Willan AR, Crowther MA. Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of prospective studies investigating symptomatic outcomes. Archives of Internal Medicine 2002;162(13):1465-71.
65. Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet 2002;359:294-302.
66. Eikelboom JW, Yusuf S. Direct thrombin inhibitors in acute coronary syndromes. Lancet 2002.
67. EMEA. European Medicines Agency. Press release AstraZeneca withdraws its application for Ximelagatran 36-mg film-coated tablets. http://www.ema.europa.eu/humandocs/PDFs/EPAR/ximelagatran/5782706en.pdf London, 16 February 2006.
68. European Medicines Agency. Questions and answers on withdrawal of the marketing application for ximelagatran AstraZeneca 36 mg film coated tablets. http://www.ema.europa.eu/humandocs/PDFs/EPAR/ximelagatran/6046506en.pdf London, 23 February 2006.
69. Eriksson BI, Kälebo P, Anthymyr BA, Wadenvik H, Tengborn L, Risberg B. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. Comparison of low-molecularweight heparin and unfractionated heparin. Journal of Bone and Joint Surgery 1991;73(4):484-93.
70. Eriksson, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. (Erratum). Lancet 2007;370:2003.
71. Singelyn FJ, Verheyen C, Piovella F, Van Aken HK, Rosencher Nadia. EXPERT Study Investigators. The safety and efficacy of extended thromboprophylaxis with fondaparinux after major orthopedic. Anesthesia and Analgesia 2007;105(6):1540-7.
72. Fitzgerald RH Jr, Spiro TE, Trowbridge AA, Gardiner GA Jr, Whitsett TL, O'Connell MB, et al. Prevention of venous thromboembolic disease following primary total knee arthroplasty: a randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin. The Journal of Bone and Joint Surgery 2001;83-A(6):900-6.
73. Francis CW, Pellegrini VD Jr, Leibert KM, Totterman S, Azodo MV, Harris CM, et al. Comparison of two warfarin regimens in the prevention of venous thrombosis following total knee replacement. Thrombosis and Haemostasis 1996;75(5):706-11.
74. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA Jr, et al. Prevention of venous thromboembolism. Chest 2001;119(Suppl 1):132S-175S.
75. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, et al. Prevention of Venous Thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:338S-400S.
76. Gross M, Anderson DR, Nagpal S, O'Brien B. Venous thromboembolism prophylaxis after total hip or knee arthroplasty: a survey of Canadian orthopedic surgeons. Canadian Journal of Surgery 1999;42(6):457-61.
77. Guyatt GH, Sackett DL, Cook DJ. Users' guides to the medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA 1993;270(21):2598-601.
78. Guyatt GH, Sackett DL, Cook DJ. Useŕs guide to the medical literature. II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group. JAMA 1994;271(1):59-63.
79. Albers GW, Diener HC, Frison L, Grind M, Nevison M, Partridge S, et al. SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005;293(6):690-8.
80. Hamulyak K, Lensing AW, van der Meer J, Smid WM, van Ooy A, Hoek JA. Subcutaneous low-molecular weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? Fraxiparine Oral Anticoagulant Study Group. Thrombosis and Haemostasis 1995;74(6):1428-31.
81. Handoll HH, Farrar MJ, McBirnie J, Tytherleigh-Strong G, Milne AA, Gillespie WJ. Heparin, low molecular weight heparin and physical methods for preventing deep vein thrombosis and pulmonary embolism following surgery for hip fractures. Cochrane Database of Systematic Reviews 2002, Issue 4. [Art. No.: CD000305. DOI: 10.1002/14651858.CD000305]
82. Heit JA, Berkowitz SD, Bona R, Cabanas V, Corson JD, Elliott CG, et al. Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind, dose-ranging study. Thrombosis and Haemostasis 1997;77(1):32-8.
83. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
84. Hill J, Treasure T. Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients having surgery: summary of NICE guidance. BMJ 2007;334(7602):1053-4.
85. Hirsh J, Dalen JF, Anderson DR, Poller L, Bussey H, Ansell J, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001 2001;119(Suppl 1):8S-21S.
86. Holmes M, Carroll C, Papaioannou D. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: A Single Technology Appraisal. School of Health and Related Research (ScHARR), The University of Sheffield 2008:1-150.
87. Hull R, Raskob G, Pineo G, Rosenbloom D, Evans W, Mallory T, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. New England Journal of Medicine 1993;329(19):1370-6.
88. Hull RD, Pineo GF, Stein PD, Mah AF, MacIsaac SM, Dahl OE, et al. Timing of initial administration of lo-molecular-weight-heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. Archives of Internal Medicine 2001;161(16):1952-60.
89. Hull RD, Pineo GF, Stein PD, Mah AF, MacIsaac SM, Dahl OE, et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Annals of Internal Medicine 2001;135(10):858-69.
90. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomised clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1-12.
91. Lazerow SK, Abdi MS, Lewis JH. Drug-induced liver disease 2004. Current Opinion in Gastroenterology 2005;21(3):283-92.
92. Leclerc JR, Geerts WH, Desjardins L, Jobin F, Laroche F, Delorme F, et al. Prevention of deep vein thrombosis after mayor knee surgery: a randomized, doubled-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo. Thrombosis & Haemostasis 1992;67(4):417-23.
93. Leclerc JR, Geerts WH, Desjardins L, Laflamme GH, L'esperance B, Demers C, et al. Prevention of venous thromboembolism after knee arthroplasty: a randomized, double-blind trial comparing enoxaparin with warfarin. Annals of Internal Medicine 1996;124(7):619-26.
94. Leclerc JR, Gent M, Hirsh J, Geerts WH, Ginsberg J. The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Canadian Collaborative Group. Archives of Internal Medicine 1998;158(8):873-8.
95. Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Archives of Internal Medicine 2003;163(15):1849-56.
96. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute 1959;22(4):719-48.
97. Mesko JW, Brand RA, Iorio R, Gradisar I, Reekin R, Leighton R. Venous thromboembolic disease management patterns in total hip arthroplasty and total knee arthroplasty patients: a survey of the AAHKS membership. Journal of Arthroplasty 2001;16(6):679-88.
98. Moher D, Jadad AR, Nichol G, Perman M, Tugwell T, Walsh S. Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. Controlled Clinical Trials 1995;16(1):62-73.
99. National Institute for Health and Clinical Excellence. Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults. NICE technology appraisal guidance 157 - http://www.nice.org.uk/TA157 September 2008:1-26.
100. Olsson SB, Petersen P on behalf of the SPORTIF II and IV investigators. Ximelagatran: a long-term oral direct thrombin inhibitor for stroke and systemic embolism prevention in nonvalvular atrial fibrillation patients. European Heart Journal 2002;23(suppl):239.
101. Olsson SB. Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003;362(9397):1691-8.
102. O'Brien CL, Gage BF. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA 2005;293(6):699-706.
103. ÓDonnell M, Linkins LA, Kearon C, Julian J, Hirsh J, et al. Reduction of out-of-hospital symptomatic venous thromboembolism by extended thromboprophylaxis with low-molecular-weight heparin following elective hip arthroplasty: a systematic review. Archives of Internal Medicine 2003;163(11):1362-6.
104. Pellegrini VD Jr, Clement D, Lush-Ehmann C, Keller GS, Evarts CM. Natural history of thromboembolic disease after total hip arthroplasty. Clinical Orthopaedics and Related Research 1996;333:27-40.
105. Pengo V, Pegoraro C, Iliceto S. New trends in anticoagulant therapy. Israel Medical Association Journal 2004;6(8):479-81.
106. Petersen P, Grind M, Adler J. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. Journal of the American College of Cardiology 2003;41(9):1445-51.
107. Schulman S, Wahlander K, Lundstrom T, Clason SB, Eriksson H. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. New England Journal of Medicine 2003;349(18):1713-21.
108. Seagroatt V, Tan HS, Goldacre M, Bulstrode C, Nugent I, Gill L. Elective total hip replacement: incidence, emergency readmission rate, and postoperative mortality. BMJ 1991;303(6815):1431-5.
109. Scottish Intercollegiate Guidelines Network (SIGN). Prophylaxis of venous thromboembolism. A national clinical guideline. Edinburgh (Scotland). Scottish Intercollegiate Guidelines Network (SIGN) 2002 Oct;47 p (SIGN publication; no.62).
110. Spell-LeSane D Executive Secretary, Borer JS, Acting Chairman. Department Of Health And Human Services. Food And Drug Administration Center For Drug Evaluation And Research. Cardiovascular And Renal Drugs Advisory Committee. Committee meeting on Ximelagatran (Exanta). www.fda.gov/ohrms/dockets/ac/04/transcripts/2004-4069T1.htm September 10, 2004 (accessed May 2005).
111. Stringer MD, Steadman CA, Hedges AR, Thomas EM, Morley TR, Kakkar VV. Deep vein thrombosis after elective knee surgery. An incidence study in 312 patients. Journal of Bone & Joint Surgery - British Volume 1989;71(3):492-7.
112. Weitz JI, Buller HR. Direct thrombin inhibitors in acute coronary syndromes: present and future. Circulation 2002;105(8):1004-11.
113. Weitz JI, Crowther M. Direct thrombin inhibitors. Thrombosis Research 2002;106(3):V275-84.
114. Weitz JI, Hirsh J, Samama MM. New anticoagulants drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. CHEST 2004 2004;126(3 Suppl):265S-286S.
115. White RH, Romano PS, Zhou H, Rodrigo J, Bargar W. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Archives of Internal Medicine 1998;158(14):1525-31.